A detailed history of Black Rock Inc. transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 812,895 shares of INMB stock, worth $5.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
812,895
Previous 240,166 238.47%
Holding current value
$5.08 Million
Previous $2.82 Million 154.13%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$7.15 - $11.84 $4.1 Million - $6.78 Million
572,729 Added 238.47%
812,895 $7.17 Million
Q1 2024

May 10, 2024

SELL
$10.53 - $14.01 $187,044 - $248,859
-17,763 Reduced 6.89%
240,166 $2.82 Million
Q4 2023

Feb 13, 2024

BUY
$6.6 - $11.52 $165,693 - $289,209
25,105 Added 10.78%
257,929 $2.9 Million
Q3 2023

Nov 13, 2023

SELL
$6.61 - $10.9 $45,007 - $74,218
-6,809 Reduced 2.84%
232,824 $1.58 Million
Q2 2023

Aug 11, 2023

BUY
$6.5 - $10.09 $31,908 - $49,531
4,909 Added 2.09%
239,633 $2.18 Million
Q1 2023

May 12, 2023

SELL
$6.01 - $10.18 $3,612 - $6,118
-601 Reduced 0.26%
234,724 $1.52 Million
Q4 2022

Feb 13, 2023

BUY
$6.13 - $7.96 $12,762 - $16,572
2,082 Added 0.89%
235,325 $1.49 Million
Q3 2022

Nov 14, 2022

SELL
$6.04 - $10.44 $5,297 - $9,155
-877 Reduced 0.37%
233,243 $1.45 Million
Q2 2022

Aug 12, 2022

BUY
$5.48 - $8.97 $11,623 - $19,025
2,121 Added 0.91%
234,120 $2.07 Million
Q1 2022

May 12, 2022

SELL
$6.42 - $11.39 $8,127 - $14,419
-1,266 Reduced 0.54%
231,999 $1.95 Million
Q4 2021

Feb 10, 2022

BUY
$9.97 - $20.38 $865,754 - $1.77 Million
86,836 Added 59.3%
233,265 $2.38 Million
Q3 2021

Nov 09, 2021

SELL
$14.13 - $27.85 $530,963 - $1.05 Million
-37,577 Reduced 20.42%
146,429 $2.84 Million
Q2 2021

Aug 11, 2021

BUY
$9.29 - $19.33 $1.71 Million - $3.56 Million
184,006 New
184,006 $3.23 Million

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $112M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.